OBJECTIVE: To characterize the antiinflammatory function of high-density lipoprotein (HDL) in patients with rheumatoid arthritis (RA) and to identify specific differences in HDL-associated proteins and enzymes that distinguish proinflammatory HDL from normal, antiinflammatory HDL. METHODS: We studied 132 RA patients. The antiinflammatory function of HDL was assessed by a cell-free assay, and proinflammatory HDL was defined by an HDL inflammatory index > or =1. Plasma and HDL-associated protein levels of apolipoprotein A-I (Apo A-I), haptoglobin, hemopexin, hemoglobin, and myeloperoxidase (MPO) were measured by direct and sandwich enzyme-linked immunosorbent assays, respectively. Lecithin:cholesterol acyltransferase (LCAT) activity was measured by a commercially available assay. RESULTS: Age, disease activity, the presence of erosive disease, non-Caucasian race, and smoking were significantly associated with proinflammatory HDL on multivariate analysis. Patients with proinflammatory HDL had higher measures of systemic inflammation, and a significant correlation was observed between RA disease activity (using the Disease Activity Score in 28 joints) and the HDL inflammatory index (r = 0.54, P < 0.0001). Compared with patients with antiinflammatory HDL, patients with proinflammatory HDL had significantly higher levels of haptoglobin, hemoglobin, Apo A-I, and MPO associated with HDL (P < 0.05 for all comparisons except MPO, which was P = 0.05). LCAT activity was lowest in patients with proinflammatory HDL, but was also significantly reduced in RA patients with antiinflammatory HDL as compared with healthy controls (P = 0.001). CONCLUSION: Proinflammatory HDL in this RA patient cohort was associated with active disease and an altered protein cargo as compared with antiinflammatory HDL in RA patients and in healthy controls. The antiinflammatory function of HDL was inversely correlated with systemic inflammation in RA patients and may warrant further investigation as a mechanism by which active RA increases cardiovascular morbidity and mortality.
OBJECTIVE: To characterize the antiinflammatory function of high-density lipoprotein (HDL) in patients with rheumatoid arthritis (RA) and to identify specific differences in HDL-associated proteins and enzymes that distinguish proinflammatory HDL from normal, antiinflammatory HDL. METHODS: We studied 132 RApatients. The antiinflammatory function of HDL was assessed by a cell-free assay, and proinflammatory HDL was defined by an HDL inflammatory index > or =1. Plasma and HDL-associated protein levels of apolipoprotein A-I (Apo A-I), haptoglobin, hemopexin, hemoglobin, and myeloperoxidase (MPO) were measured by direct and sandwich enzyme-linked immunosorbent assays, respectively. Lecithin:cholesterol acyltransferase (LCAT) activity was measured by a commercially available assay. RESULTS: Age, disease activity, the presence of erosive disease, non-Caucasian race, and smoking were significantly associated with proinflammatory HDL on multivariate analysis. Patients with proinflammatory HDL had higher measures of systemic inflammation, and a significant correlation was observed between RA disease activity (using the Disease Activity Score in 28 joints) and the HDL inflammatory index (r = 0.54, P < 0.0001). Compared with patients with antiinflammatory HDL, patients with proinflammatory HDL had significantly higher levels of haptoglobin, hemoglobin, Apo A-I, and MPO associated with HDL (P < 0.05 for all comparisons except MPO, which was P = 0.05). LCAT activity was lowest in patients with proinflammatory HDL, but was also significantly reduced in RApatients with antiinflammatory HDL as compared with healthy controls (P = 0.001). CONCLUSION: Proinflammatory HDL in this RApatient cohort was associated with active disease and an altered protein cargo as compared with antiinflammatory HDL in RApatients and in healthy controls. The antiinflammatory function of HDL was inversely correlated with systemic inflammation in RApatients and may warrant further investigation as a mechanism by which active RA increases cardiovascular morbidity and mortality.
Authors: M Navab; S Y Hama; C J Cooke; G M Anantharamaiah; M Chaddha; L Jin; G Subbanagounder; K F Faull; S T Reddy; N E Miller; A M Fogelman Journal: J Lipid Res Date: 2000-09 Impact factor: 5.922
Authors: B J Radovits; D A Popa-Diaconu; C Popa; A Eijsbouts; R F J M Laan; P L C M van Riel; J Fransen Journal: Ann Rheum Dis Date: 2008-08-13 Impact factor: 19.103
Authors: Christina Charles-Schoeman; Mona Lisa Banquerigo; Susan Hama; Mohamad Navab; Grace S Park; Brian J Van Lenten; Alan C Wagner; Alan M Fogelman; Ernest Brahn Journal: Clin Immunol Date: 2008-03-12 Impact factor: 3.969
Authors: Angel Gonzalez; Hilal Maradit Kremers; Cynthia S Crowson; Paulo J Nicola; John M Davis; Terry M Therneau; Veronique L Roger; Sherine E Gabriel Journal: Arthritis Rheum Date: 2007-11
Authors: Junji Watanabe; Katherine J Chou; James C Liao; Yunan Miao; Hsiang-Hui Meng; Helen Ge; Victor Grijalva; Susan Hama; Kathy Kozak; Georgette Buga; Julian P Whitelegge; Terry D Lee; Robin Farias-Eisner; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy Journal: J Biol Chem Date: 2007-06-07 Impact factor: 5.157
Authors: C Popa; L J H van Tits; P Barrera; H L M Lemmers; F H J van den Hoogen; P L C M van Riel; T R D J Radstake; M G Netea; M Roest; A F H Stalenhoef Journal: Ann Rheum Dis Date: 2008-07-17 Impact factor: 19.103
Authors: Leanne T Bloedon; Richard Dunbar; Danielle Duffy; Paula Pinell-Salles; Robert Norris; Bruce J DeGroot; Rajesh Movva; Mohamad Navab; Alan M Fogelman; Daniel J Rader Journal: J Lipid Res Date: 2008-03-06 Impact factor: 5.922
Authors: Christina Charles-Schoeman; Yuen Yin Lee; Victor Grijalva; Sogol Amjadi; John FitzGerald; Veena K Ranganath; Mihaela Taylor; Maureen McMahon; Harold E Paulus; Srinivasa T Reddy Journal: Ann Rheum Dis Date: 2012-01-20 Impact factor: 19.103
Authors: György Kerekes; Michael T Nurmohamed; Miguel A González-Gay; Ildikó Seres; György Paragh; Zsófia Kardos; Zsuzsa Baráth; László Tamási; Pál Soltész; Zoltán Szekanecz Journal: Nat Rev Rheumatol Date: 2014-08-05 Impact factor: 20.543
Authors: Anuradha Vivekanandan-Giri; Jessica L Slocum; Jaeman Byun; Chongren Tang; Robin L Sands; Brenda W Gillespie; Jay W Heinecke; Rajiv Saran; Mariana J Kaplan; Subramaniam Pennathur Journal: Ann Rheum Dis Date: 2013-01-12 Impact factor: 19.103
Authors: Theodoros Kelesidis; Nicholas Jackson; Grace A McComsey; Xiaoyan Wang; David Elashoff; Michael P Dube; Todd T Brown; Otto O Yang; James H Stein; Judith S Currier Journal: AIDS Date: 2016-11-13 Impact factor: 4.177